🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis

    phase 2 small molecule completed

    1 trial

  2. Mebendazole

    Krystal Biotech Netherlands B.V.

    Pilomyxoid Astrocytoma

    phase 2 small molecule completed

    1 trial

  3. Medtronic PrimeADVANCED Neurostimulator

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 2 other completed

    1 trial

  4. Mitapivat

    Agios Netherlands B.V.

    Anemia

    phase 2 small molecule active

    1 trial

  5. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

  6. Modakafusp Alfa

    Teva Generics B.V

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  7. NX210c, GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  8. ORSERDU 86 mg film-coated tablets, ABEMACICLIB, ABEMACICLIB, ORSERDU 345 mg film-coated tablets, ABEMACICLIB

    Stemline Therapeutics B.V.

    Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  9. ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Stemline Therapeutics B.V.

    metastatic breast cancer

    phase 2 small molecule active

    1 trial

  10. P276-00

    Piramal Critical Care B.V.

    Melanoma

    phase 2 small molecule completed

    1 trial

  11. PCI

    Rhythm Pharmaceuticals Netherlands B.V.

    Myocardial Infarction

    phase 2 other completed

    1 trial

  12. PROLEUKIN 18 millions U.I., poudre pour solution injectable, CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  13. PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion, Lifileucel, Cyclophosphamide Injection 1 g, FLUDARABINE

    Iovance Biotherapeutics B.V.

    Previously treated advanced melanoma

    phase 2 small molecule active

    1 trial

  14. Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  15. Patisiran

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  16. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    2 trials

  17. Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy

    phase 2 small molecule completed

    1 trial

  18. Pegcetacoplan

    Apellis Europe B.V.

    Neovascular Age-related Macular Degeneration

    phase 2 small molecule terminated

    2 trials

  19. Pegcetacoplan

    Apellis Europe B.V.

    Transplant-Associated Thrombotic Microangiopathy

    phase 2 small molecule completed

    1 trial

  20. Pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule terminated

    1 trial

  21. Pemetrexed

    Samsung Bioepis NL B.V.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  22. Phosphate buffered saline for SC administration

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  23. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  24. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources